Aspira Women's Health Inc.
AWHL Healthcare Diagnostics & Research
In the quarter to June 2026, revenue fell 14.9%, EPS grew 28.6%, free cash flow fell 24.6% and total debt rose 25.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AWHL
Aspira Women's Health Inc. (AWHL) EV/Sales
As of 15 October 2026, Aspira Women's Health Inc. (AWHL) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from −0.1× (April 2025) to 195× (February 2021); the current reading is higher than 9% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.3× | 106.21% |
| FY2024 | 1.1× | (72.93%) |
| FY2023 | 4.2× | 24.54% |
| FY2022 | 3.4× | (86.00%) |
| FY2021 | 24.0× | (83.21%) |
| FY2020 | 143× | 978.98% |
| FY2019 | 13.2× | 207.16% |
| FY2018 | 4.3× | (86.37%) |
| FY2017 | 31.6× | 54.54% |
| FY2016 | 20.5× | (33.92%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.3× | 17.41% |
| Mar 2026 | 2.0× | (16.22%) |
| Dec 2025 | 2.3× | 41.86% |
| Sep 2025 | 1.6× | 186.30% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| AWHL Aspira Women's Health Inc. | 1.4× |
| NOTVQ Inotiv, Inc. compare | 1.6× |
| PRPH ProPhase Labs, Inc. compare | 1.8× |
| NDRA ENDRA Life Sciences Inc. compare | 2.2× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)